These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 26428262)

  • 21. Microdosing: a valuable tool for accelerating drug development and the role of bioanalytical methods in meeting the challenge.
    Ings RM
    Bioanalysis; 2009 Oct; 1(7):1293-305. PubMed ID: 21083052
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Forced degradation and impurity profiling: recent trends in analytical perspectives.
    Jain D; Basniwal PK
    J Pharm Biomed Anal; 2013 Dec; 86():11-35. PubMed ID: 23969330
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Microdosing, isotopic labeling, radiotracers and metabolomics: relevance in drug discovery, development and safety.
    Wotherspoon AT; Safavi-Naeini M; Banati RB
    Bioanalysis; 2017 Dec; 9(23):1913-1933. PubMed ID: 29171759
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Human microdosing; a boon or a bane?
    Seth SD; Kumar NK; Dua P
    Indian J Med Res; 2009 Aug; 130(2):202-4. PubMed ID: 19797820
    [No Abstract]   [Full Text] [Related]  

  • 25. Practical experience of using human microdosing with AMS analysis to obtain early human drug metabolism and PK data.
    Garner RC
    Bioanalysis; 2010 Mar; 2(3):429-40. PubMed ID: 21083253
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Positron emission tomography for use in microdosing studies.
    Wagner CC; Müller M; Lappin G; Langer O
    Curr Opin Drug Discov Devel; 2008 Jan; 11(1):104-10. PubMed ID: 18175273
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Promoting, improving and accelerating the drug development and approval processes.
    Graul AI
    Drug News Perspect; 2007; 20(1):45-55. PubMed ID: 17332899
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical pharmacokinetics: current requirements and future perspectives from a regulatory point of view.
    Shah RR
    Xenobiotica; 1993 Nov; 23(11):1159-93. PubMed ID: 8310705
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost-effectiveness analysis of microdose clinical trials in drug development.
    Yamane N; Igarashi A; Kusama M; Maeda K; Ikeda T; Sugiyama Y
    Drug Metab Pharmacokinet; 2013; 28(3):187-95. PubMed ID: 22971640
    [TBL] [Abstract][Full Text] [Related]  

  • 30. How pharmacogenomics (PG) are changing practice: implications for prescribers, their patients, and the healthcare system (PG series part I).
    Preskorn SH; Hatt CR
    J Psychiatr Pract; 2013 Mar; 19(2):142-9. PubMed ID: 23507814
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Development and validation of a liquid chromatography-tandem mass spectrometry analytical method for the therapeutic drug monitoring of eight novel anticancer drugs.
    Herbrink M; de Vries N; Rosing H; Huitema ADR; Nuijen B; Schellens JHM; Beijnen JH
    Biomed Chromatogr; 2018 Apr; 32(4):. PubMed ID: 29165815
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetic drug interaction studies must consider pharmacological heterogeneity, use of repeated dosing, and translation into a message understandable to practicing clinicians.
    de Leon J; Spina E; Diaz FJ
    J Clin Psychopharmacol; 2009 Jun; 29(3):201-5. PubMed ID: 19440070
    [No Abstract]   [Full Text] [Related]  

  • 33. A positron emission tomography microdosing study with a potential antiamyloid drug in healthy volunteers and patients with Alzheimer's disease.
    Bauer M; Langer O; Dal-Bianco P; Karch R; Brunner M; Abrahim A; Lanzenberger R; Hofmann A; Joukhadar C; Carminati P; Ghirardi O; Piovesan P; Forloni G; Corrado ME; Lods N; Dudczak R; Auff E; Kletter K; Müller M
    Clin Pharmacol Ther; 2006 Sep; 80(3):216-27. PubMed ID: 16952488
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Clinical evaluation of therapeutic drug monitoring].
    Kohno H
    Nihon Rinsho; 2004 Dec; 62 Suppl 12():351-5. PubMed ID: 15658336
    [No Abstract]   [Full Text] [Related]  

  • 35. Opportunities to optimize tacrolimus therapy in solid organ transplantation: report of the European consensus conference.
    Wallemacq P; Armstrong VW; Brunet M; Haufroid V; Holt DW; Johnston A; Kuypers D; Le Meur Y; Marquet P; Oellerich M; Thervet E; Toenshoff B; Undre N; Weber LT; Westley IS; Mourad M
    Ther Drug Monit; 2009 Apr; 31(2):139-52. PubMed ID: 19177031
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Less is more: the human microdosing concept.
    Garner RC
    Drug Discov Today; 2005 Apr; 10(7):449-51. PubMed ID: 15809185
    [No Abstract]   [Full Text] [Related]  

  • 37. Lessons learned from independent central review.
    Ford R; Schwartz L; Dancey J; Dodd LE; Eisenhauer EA; Gwyther S; Rubinstein L; Sargent D; Shankar L; Therasse P; Verweij J
    Eur J Cancer; 2009 Jan; 45(2):268-74. PubMed ID: 19101138
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of microdosing strategies for studies in preclinical drug development: demonstration of linear pharmacokinetics in dogs of a nucleoside analog over a 50-fold dose range.
    Sandhu P; Vogel JS; Rose MJ; Ubick EA; Brunner JE; Wallace MA; Adelsberger JK; Baker MP; Henderson PT; Pearson PG; Baillie TA
    Drug Metab Dispos; 2004 Nov; 32(11):1254-9. PubMed ID: 15286054
    [TBL] [Abstract][Full Text] [Related]  

  • 39. American College of Clinical Pharmacology position statement on the use of microdosing in the drug development process.
    Bertino JS; Greenberg HE; Reed MD;
    J Clin Pharmacol; 2007 Apr; 47(4):418-22. PubMed ID: 17389550
    [No Abstract]   [Full Text] [Related]  

  • 40. Commentary on ACCP position statement on the use of microdosing in the drug development process.
    Rowland M
    J Clin Pharmacol; 2007 Dec; 47(12):1595-6; author reply 1597-8. PubMed ID: 18048576
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.